Skip to main content
OpenTrials

Clinical trial condition

Congenital Bleeding Disorder

Explore clinical trials studying Congenital Bleeding Disorder. Study availability and eligibility vary by location and protocol.

85 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Congenital Bleeding Disorder trial results

Completed

A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors

NCT03196284

Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Locations
  • Novo Nordisk Investigational Site Los Angeles, California, United States
  • Novo Nordisk Investigational Site Indianapolis, Indiana, United States
  • Novo Nordisk Investigational Site Iowa City, Iowa, United States
  • Novo Nordisk Investigational Site Vienna, Austria
View all 22 locations
View Trial Details
Completed

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A

NCT01493778

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations
  • Novo Nordisk Investigational Site Phoenix, Arizona, United States
  • Novo Nordisk Investigational Site Long Beach, California, United States
  • Novo Nordisk Investigational Site Sacramento, California, United States
  • Novo Nordisk Investigational Site Washington D.C., District of Columbia, United States
View all 69 locations
View Trial Details
Completed

A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A

NCT01731600

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations
  • Novo Nordisk Investigational Site Phoenix, Arizona, United States
  • Novo Nordisk Investigational Site Long Beach, California, United States
  • Novo Nordisk Investigational Site Orange, California, United States
  • Novo Nordisk Investigational Site Washington D.C., District of Columbia, United States
View all 51 locations
View Trial Details
Completed

Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A

NCT01480180

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations
  • Novo Nordisk Investigational Site Phoenix, Arizona, United States
  • Novo Nordisk Investigational Site Long Beach, California, United States
  • Novo Nordisk Investigational Site Sacramento, California, United States
  • Novo Nordisk Investigational Site Torrance, California, United States
View all 93 locations
View Trial Details
Completed

Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.

NCT01489111

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations
  • Novo Nordisk Investigational Site Phoenix, Arizona, United States
  • Novo Nordisk Investigational Site Long Beach, California, United States
  • Novo Nordisk Investigational Site Sacramento, California, United States
  • Novo Nordisk Investigational Site Torrance, California, United States
View all 70 locations
View Trial Details
Completed

Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A

NCT02938585

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations
  • Novo Nordisk Investigational Site Beijing, Beijing Municipality, China
  • Novo Nordisk Investigational Site Chonqqing, Chongqing Municipality, China
  • Novo Nordisk Investigational Site Fuzhou, Fujian, China
  • Novo Nordisk Investigational Site Guangzhou, Guangdong, China
View Trial Details
Completed

Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A

NCT02035384

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations
  • Novo Nordisk Investigational Site Mobile, Alabama, United States
  • Novo Nordisk Investigational Site Torrance, California, United States
  • Novo Nordisk Investigational Site Peoria, Illinois, United States
  • Novo Nordisk Investigational Site Albuquerque, New Mexico, United States
View all 41 locations
View Trial Details
Completed

Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period

NCT03449342

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations
  • Novo Nordisk Investigational Site Bangalore, Karnataka, India
  • Novo Nordisk Investigational Site Kochi, Kerala, India
  • Novo Nordisk Investigational Site Mumbai, Maharashtra, India
  • Novo Nordisk Investigational Site Pune, Maharashtra, India
View Trial Details
Completed

Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A

NCT02994407

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations
  • Novo Nordisk Investigational Site Orlando, Florida, United States
  • Novo Nordisk Investigational Site Iowa City, Iowa, United States
  • Novo Nordisk Investigational Site East Lansing, Michigan, United States
  • Novo Nordisk Investigational Site Cleveland, Ohio, United States
View all 19 locations
View Trial Details

Related conditions